And some patients simply do not want their long-term weight loss plan to depend on taking medication indefinitely
2021;10:R20012
People with treatment-resistant hypertension, especially those with co-existing diabetes, obesity, heart failure (HF), or chronic kidney disease (CKD) may particularly benefit from SGLT2-i and GLP-1RA
[DOI] [PMC free article] [PubMed] [Google Scholar] 164.Liu J., Aylor K.W., Liu Z
Maintaining weight loss If you are prescribed a weight-loss medication, board-certified providers will continue to evaluate you and may slowly adjust the dose about every four weeks to find the right dose that works best for you
CMS is proposing temporary expansions of Medicare and Medicaid coverage of GLP-1s for obesity through demonstration programs CMS initially proposed a two-step approach to expanding coverage of GLP-1s for obesity in Medicare a temporary payment demonstration for 2026, known as the Medicare GLP-1 Bridge, and a new Center for Medicare and Medicaid Innovation (CMMI) model, known as the BALANCE Model, that was originally scheduled to begin in January 2027 and end in December 2031